5 and <2.9 log10 IU/mL. The latter were excluded from the analysis as previous vaccination could not be ruled out in individuals with borderline titres (Fig. 1). Their results were disregarded to ensure the reference

group contained only primo-vaccinated subjects. Post-vaccination seropositivity among the 40 subjects excluded because of yellow fever high or borderline titres before vaccination was 89.7%, whereas for those seronegative it was 93.7%. As shown in Table 2, approximately 93% of volunteers in the reference group became seropositive after vaccination. The percentage of subjects with neutralising antibody titres ≥2.9 log10 IU/mL decreased gradually from 1–4 years up to 10–11 years post-vaccination. However, there was an unexpected increase in the proportion of seropositive subjects in the subgroup vaccinated for ≥12 years (Table 2). The distribution of antibody titres according to the elapsed time since vaccination and the BIBF 1120 cost corresponding GMT showed higher titres in newly vaccinated subjects (up to 45 days) decreasing sharply in 1–4 years and slightly in 10–11 years, and followed by an unexpected slight increase in subjects at ≥12 years post-vaccination

(Fig. 2 and Table 3). The decreasing trend in antibody titres with the time since vaccination appeared strongly modified by age as the data showing a significant decline in antibody titres after one year were available only for 18–30-year-old Talazoparib ic50 subjects (Fig. 3). An increasing trend

in the mean titres across age groups was disclosed in volunteers with 10–11 years and ≥12 years post-vaccination. The percentage of subjects with anti-dengue IgG titres > 1:40 was 61.9%, overall, and 89.0% among subjects from Rio de Janeiro and 13.7% for Alfenas residents. There was no apparent correlation between the immunological statuses for dengue and yellow PDK4 fever, as the rate of yellow fever seropositives by PRNT was similar to that of seropositives and seronegatives (IgG) for dengue (Table 4). The distribution of post-vaccination titres was somewhat skewed for higher values in dengue-IgG positive subjects, whose yellow fever antibody GMT was 3118 IU/mL (95%C.I.: 2756–3527), whereas dengue IgG negative subjects had a GMT 2445 IU/mL (95% C.I.: 2094–2860). However, the comparability of dengue IgG positive and negative subgroups was confounded by age and time since vaccination. In the multivariate analysis, only the elapsed time since vaccination had a significant correlation with the antibody titres (using the multiple regression model) and with positive serology for yellow fever (using the logistic regression model). Consistent with the effects of the elapsed time since vaccination and age on antibody titres shown in Fig. 3, the interaction term of those two independent variables in the multiple regression model was statistically significant (p < 0.001).